{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:35:48Z","timestamp":1794702948946,"version":"4.9.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.04.078","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T20:15:42Z","timestamp":1494101742000},"page":"3286-3294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d \u2013 Potential and limitations"],"prefix":"10.1016","volume":"35","author":[{"given":"Michael","family":"Br\u00f6ker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Vojtek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.078_b0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/aje\/kwh082","article-title":"Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases","volume":"159","author":"O'Brien","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/14712598.2012.725718","article-title":"Glycoconjugate vaccines","volume":"13","author":"Pace","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2017.04.078_b0015","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants","volume":"56","author":"Gold","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.04.078_b0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.04.078_b0025","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/cb400423g","article-title":"Recent mechanistic insights on glycoconjugate vaccines and future perspectives","volume":"8","author":"Berti","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0030","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/15680266113136660180","article-title":"Novel strategies for development of next-generation glycoconjugate vaccines","volume":"13","author":"Avci","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.vaccine.2017.04.078_b0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.04.078_b0040","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/IAI.45.3.582-591.1984","article-title":"Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates","volume":"45","author":"Schneerson","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1128\/IAI.52.2.519-528.1986","article-title":"Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates","volume":"52","author":"Schneerson","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.04.078_b0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0060","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4161\/hv.20211","article-title":"The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study","volume":"8","author":"Dbaibo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2017.04.078_b0070","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS ONE"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2017.04.078_b0075","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1093\/cid\/civ512","article-title":"MenAfriVac as an antitetanus vaccine","volume":"61","author":"Borrow","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0080","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1128\/IAI.58.7.2309-2312.1990","article-title":"Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid","volume":"58","author":"Fattom","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0085","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/INF.0b013e31822d28df","volume":"30","author":"Wheeler","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.078_b0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Br\u00f6ker","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.04.078_b0095","first-page":"1808","article-title":"Factors contributing to the immunogenicity of meningococcal conjugate vaccines","volume":"12","author":"Br\u00f6ker","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0100","first-page":"79","article-title":"Et al.","volume":"3","author":"Podda","year":"1991","journal-title":"Ann Ig"},{"key":"10.1016\/j.vaccine.2017.04.078_b0105","first-page":"243","article-title":"Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study","volume":"25","author":"Halperin","year":"2002","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.vaccine.2017.04.078_b0110","first-page":"1","article-title":"Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents","volume":"5","author":"Gasparini","year":"2014","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.vaccine.2017.04.078_b0115","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/S0264-410X(03)00058-6","article-title":"Effect of infant immunisation with meningococcus serogroup C-CRM197 conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children","volume":"21","author":"McVernon","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0120","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/j.vaccine.2016.10.020","article-title":"Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: a randomised controlled trial","volume":"34","author":"Tashani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0125","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0264-410X(01)00375-9","article-title":"Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers","volume":"20","author":"Olander","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","article-title":"A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial","volume":"93","author":"Pace","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2017.04.078_b0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom","volume":"16","author":"Southern","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0140","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/21645515.2015.1086048","article-title":"Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and cross reacting material 197 (CRM197) when used as carrier proteins in glycoconjugates","volume":"12","author":"Br\u00f6ker","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0145","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0150","unstructured":"GlaxoSmithKline Biologicals SA. Synflorix summary of product characteristics. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000973\/WC500054346.pdf> [accessed on 29 August 2016]."},{"key":"10.1016\/j.vaccine.2017.04.078_b0155","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1086\/527396","article-title":"Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines","volume":"46","author":"Forsgren","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0160","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1128\/IAI.64.11.4586-4592.1996","article-title":"Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae","volume":"64","author":"Akkoyunlu","year":"1996","journal-title":"Infect Immun"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.04.078_b0165","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0264-410X(00)00288-7","article-title":"Developing a nontypeable Haemophilus influenzae (NTHi) vaccine","volume":"19","author":"Poolman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0170","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/IAI.67.6.2746-2762.1999","article-title":"Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection","volume":"67","author":"Bakaletz","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0175","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1016\/j.vaccine.2015.07.034","article-title":"PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice","volume":"33","author":"Siggins","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.078_b0185","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.04.078_b0190","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2017.1287640","article-title":"Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children \u2013 a randomized controlled trial","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0195","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2214-109X(14)70224-4","article-title":"Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies","volume":"2","author":"Hammitt","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2017.04.078_b0200","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/cid\/cis922","article-title":"Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial","volume":"56","author":"van den Bergh","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jpids\/piw010","article-title":"Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media \u2013 a double-blind randomized clinical trial in Finland","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2017.04.078_b0210","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.vaccine.2010.12.086","article-title":"Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage","volume":"29","author":"Prymula","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0215","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1016\/j.vaccine.2016.09.027","article-title":"Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo, Brazil","volume":"34","author":"Brandileone","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12887-015-0483-8","article-title":"Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine","volume":"15","author":"Leach","year":"2015","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.vaccine.2017.04.078_b0225","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijporl.2016.05.011","article-title":"General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines","volume":"86","author":"Leach","year":"2016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2431-14-200","article-title":"Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules","volume":"14","author":"Leach","year":"2014","journal-title":"BMC Pediatr"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2017.04.078_b0235","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0240","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0245","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/INF.0b013e3181fcb2bf","article-title":"Immunogenicity and safety of an investigational combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine","volume":"30","author":"Nolan","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.078_b0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3476(05)81186-2","article-title":"Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants","volume":"121","author":"Granoff","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2017.04.078_b0255","unstructured":"Merck Sharp & Dohme Corp. Liquid PedvaxHIB. <http:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/pedvax_hib\/pedvax_pi.pdf> [accessed on June 10, 2016]."},{"key":"10.1016\/j.vaccine.2017.04.078_b0260","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1586\/erv.11.142","article-title":"Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules","volume":"10","author":"Borrow","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.078_b0265","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0270","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0275","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.078_b0280","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","article-title":"Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants","volume":"66","author":"Dagan","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0285","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.vaccine.2016.06.038","article-title":"The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Voysey","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0290","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vaccine.2015.10.100","article-title":"Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study","volume":"34","author":"Maertens","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0295","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.vaccine.2016.04.066","article-title":"Pertussis vaccination during pregnancy in Belgium: follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age","volume":"34","author":"Maertens","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0300","first-page":"357","article-title":"A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication","volume":"6","author":"Chen","year":"1999","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2017.04.078_b0305","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/IAI.32.2.681-689.1981","article-title":"Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids","volume":"32","author":"Pavlovskis","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0310","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1128\/IAI.69.11.6962-6969.2001","article-title":"Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein","volume":"69","author":"Hertle","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0315","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/infdis\/163.5.1040","article-title":"Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans","volume":"163","author":"Cryz","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0320","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1086\/499821","article-title":"Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children","volume":"193","author":"Ahmed","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0325","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/170.4.834","article-title":"Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers","volume":"170","author":"Cross","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0330","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0264-410X(94)00009-C","article-title":"Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine","volume":"13","author":"Cryz","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0335","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/IAI.62.10.4440-4444.1994","article-title":"Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines","volume":"62","author":"Szu","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0340","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Mai","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.078_b0345","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.vaccine.2003.11.034","article-title":"Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials","volume":"22","author":"Fattom","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0350","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/IAI.52.1.161-165.1986","article-title":"Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine","volume":"52","author":"Cryz","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0355","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/IAI.56.7.1829-1830.1988","article-title":"Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans","volume":"56","author":"Cryz","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0360","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/0140-6736(91)92103-9","article-title":"Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis","volume":"338","author":"Schaad","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.078_b0365","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized Phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0370","first-page":"51","article-title":"Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli","volume":"26","author":"Ravenscroft","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2017.04.078_b0375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/infdis\/jiv429","article-title":"Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field","volume":"213","author":"Poolman","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0380","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/IAI.00157-11","article-title":"Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice","volume":"79","author":"Campodonico","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0385","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1128\/IAI.68.4.2161-2166.2000","article-title":"Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice","volume":"68","author":"Pavliakova","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0390","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/toxins6041385","article-title":"Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity","volume":"6","author":"Romano","year":"2014","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2017.04.078_b0395","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(11)61651-6","article-title":"Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis","volume":"379","author":"Edmond","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.078_b0400","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/bc500438h","article-title":"Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry","volume":"25","author":"Nilo","year":"2014","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2017.04.078_b0405","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acschembio.5b00247","article-title":"Anti-Group B Streptococcus glycan-conjugate vaccines using pilus protein GBS80 as carrier and antigen: comparing lysine and tyrosine-directed conjugation","volume":"10","author":"Nilo","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0410","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1126\/science.1109869","article-title":"Identification of a universal Group B Streptococcus vaccine by multiple genome screen","volume":"309","author":"Maione","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.078_b0415","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1021\/acs.bioconjchem.5b00365","article-title":"Exploring the effect of conjugation site and chemistry on the immunogenicity of an anti-Group B Streptococcus glycoconjugate vaccine based on GBS67 pilus protein and type V polysaccharide","volume":"26","author":"Nilo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2017.04.078_b0420","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/21645515.2015.1087625","article-title":"Rationale and prospects for novel pneumococcal vaccines","volume":"12","author":"Moffitt","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.078_b0425","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CVI.00754-12","article-title":"Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response","volume":"20","author":"Perciani","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0430","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1016\/j.vaccine.2011.08.109","article-title":"Humoral immune response of a pneumococcal conjugate vaccine: capsular polysaccharide serotype 14-Lysine modified PspA","volume":"29","author":"Santamaria","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0435","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/CVI.00807-13","article-title":"Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults","volume":"21","author":"Pauksens","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0440","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2016.06.039","article-title":"Preclinical studies on new proteins as carrier for glycoconjugate vaccines","volume":"34","author":"Tontini","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.078_b0445","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcimb.2012.00016","article-title":"Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials","volume":"2","author":"Bagnoli","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.078_b0450","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jit800","article-title":"Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli","volume":"209","author":"Wacker","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.078_b0455","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1128\/IAI.67.11.6191-6193.1999","article-title":"Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice","volume":"67","author":"Konadu","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.078_b0460","doi-asserted-by":"crossref","first-page":"e00974","DOI":"10.1128\/mBio.00974-14","article-title":"A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli","volume":"5","author":"Lu","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.04.078_b0465","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/IAI.64.7.2824-2828.1996","article-title":"Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates","volume":"64","author":"Brett","year":"1996","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T02:32:10Z","timestamp":1602037930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":93,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17305790"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d \u2013 Potential and limitations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}